BioMed Central Page 1 of 17 (page number not for citation purposes) Retrovirology Open Access Research Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors Paul J Peters 1 , Maria J Duenas-Decamp 1 , W Matthew Sullivan 1 , Richard Brown 2 , Chiambah Ankghuambom 2 , Katherine Luzuriaga 3 , James Robinson 4 , Dennis R Burton 5 , Jeanne Bell 6 , Peter Simmonds 7 , Jonathan Ball 2 and Paul R Clapham* 1 Address: 1 Center for AIDS Research, Program in Molecular Medicine and Department of Molecular Genetics and Microbiology, 373 Plantation Street, University of Massachusetts Medical School, Worcester, MA 01605, USA, 2 Microbiology and Infectious Diseases, Institute of Infection, Immunity and Inflammation, The University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK, 3 Center for AIDS Research, Program in Molecular Medicine and Department of Pediatrics, 373 Plantation Street, University of Massachusetts Medical School, Worcester, MA 01605, USA, 4 Department of Pediatrics, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA, 5 The Scripps Research Institute, Departments of Immunology and Molecular Biology, IMM2, La Jolla, CA 92037, USA, 6 Department of Neuropathology, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK and 7 Centre for Infectious Diseases, University of Edinburgh, Summerhall, Edinburgh, EH9 1QH, UK Email: Paul J Peters - Paul.Peters@umassmed.edu; Maria J Duenas-Decamp - Maria.DuenasDecamp@umassmed.edu; W Matthew Sullivan - matthew.sullivan@umassmed.edu; Richard Brown - Richard.Brown@nottingham.ac.uk; Chiambah Ankghuambom - mrxcna@nottingham.ac.uk; Katherine Luzuriaga - Katherine.Luzuriaga@umassmed.edu; James Robinson - jrobinso@tulane.edu; Dennis R Burton - burton@scripps.edu; Jeanne Bell - Jeanne.Bell@ed.ac.uk; Peter Simmonds - Peter.Simmonds@ed.ac.uk; Jonathan Ball - Jonathan.Ball@nottingham.ac.uk; Paul R Clapham* - paul.clapham@umassmed.edu * Corresponding author Abstract Background: HIV-1 R5 viruses cause most of the AIDS cases worldwide and are preferentially transmitted compared to CXCR4-using viruses. Furthermore, R5 viruses vary extensively in capacity to infect macrophages and highly macrophage-tropic variants are frequently identified in the brains of patients with dementia. Here, we investigated the sensitivity of R5 envelopes to a range of inhibitors and antibodies that block HIV entry. We studied a large panel of R5 envelopes, derived by PCR amplification without culture from brain, lymph node, blood and semen. These R5 envelopes conferred a wide range of macrophage tropism and included highly macrophage-tropic variants from brain and non-macrophage-tropic variants from lymph node. Results: R5 macrophage-tropism correlated with sensitivity to inhibition by reagents that inhibited gp120:CD4 interactions. Thus, increasing macrophage-tropism was associated with increased sensitivity to soluble CD4 and to IgG-CD4 (PRO 542), but with increased resistance to the anti- CD4 monoclonal antibody (mab), Q4120. These observations were highly significant and are consistent with an increased affinity of envelope for CD4 for macrophage-tropic envelopes. No overall correlations were noted between R5 macrophage-tropism and sensitivity to CCR5 antagonists or to gp41 specific reagents. Intriguingly, there was a relationship between increasing Published: 18 January 2008 Retrovirology 2008, 5:5 doi:10.1186/1742-4690-5-5 Received: 9 November 2007 Accepted: 18 January 2008 This article is available from: http://www.retrovirology.com/content/5/1/5 © 2008 Peters et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Retrovirology 2008, 5:5 http://www.retrovirology.com/content/5/1/5 Page 2 of 17 (page number not for citation purposes) macrophage-tropism and increased sensitivity to the CD4 binding site mab, b12, but decreased sensitivity to 2G12, a mab that binds a glycan complex on gp120. Conclusion: Variation in R5 macrophage-tropism is caused by envelope variation that predominantly influences sensitivity to reagents that block gp120:CD4 interactions. Such variation has important implications for therapy using viral entry inhibitors and for the design of envelope antigens for vaccines. Introduction HIV-1 infection is triggered by interactions between the viral envelope glycoprotein and cell surface receptor CD4 and either of the coreceptors; CCR5 or CXCR4. These interactions induce the fusion of viral and cellular mem- branes and viral entry into cells. CCR5-using (R5) viruses are mainly transmitted [1], while CXCR4-using (X4) vari- ants can be isolated from up to 50% of AIDS patients in subtype B infections and correlate with a more rapid loss of CD4 + T-cells and faster disease progression [2-5]. Among T-cells, CCR5 expression is mainly restricted to memory T-cells [6,7], while CXCR4 is more widely expressed on various CD4 + T-cell populations including naïve T-cells [6]. R5 viruses therefore target CCR5 + mem- ory T-cell populations and in the acute phase of replica- tion, decimate the populations of CD4 + memory cells in lymphoid tissue associated with the gut and other mucosa [8-10]. CCR5 is also expressed on macrophage lineage cells [7] in non-lymphoid tissues e.g. the brain [11], and R5 viruses predominantly target these cells in neural tis- sues [12-14]. When CXCR4-using viruses emerge in late disease, they colonize naïve T-cell populations that were not infected by R5 viruses [15,16]. Nonetheless, CD4 depletion and AIDS occur in patients from which only CCR5-using viruses can be isolated [17,18]. In clade C infections, CXCR4-using variants have been detected in far fewer individuals in the late stages of disease [17,19- 22]. Thus, AIDS and death presumably occurs in the absence of CXCR4-using variants for a substantial number of HIV + patients and is caused directly by R5 viruses. R5 viruses are frequently regarded as macrophage-tropic. However, several groups have reported considerable vari- ation in the cell tropism of R5 viruses [23-25]. We reported that primary HIV-1 R5 isolates varied in their capacity to infect primary macrophage cultures by over 1000-fold [25] and we first described a subset of HIV-1 R5 isolates that could infect CD4 + T-cell lines via trace amounts of CCR5 [23]. More recently, we described R5 envelopes amplified from brain and lymph node tissue of AIDS patients that also differed markedly in tropism prop- erties [26,27]. Thus R5 envelopes from brain tissue were highly macrophage-tropic and were able to exploit low amounts of CD4 and/or CCR5 for infection. They con- trasted considerably with R5 envelopes from immune tis- sue (lymph node) that conferred inefficient macrophage infection and required high amounts of CD4 for infec- tion. Moreover, these non-macrophage-tropic envelopes were more prevalent (than macrophage-tropic envelopes) amplified from immune tissue, blood or semen [27]. These results generally support earlier reports that described a small number of highly macrophage-tropic R5 virus isolates made from brain tissue [28]. Others have confirmed that envelopes amplified from brain tissue can infect cells via low CD4 levels [29,30]. However, Thomas et al. reported less compartmentalized variation of R5 macrophage tropism, with macrophage-tropic R5 enve- lopes present in both lymphoid and brain tissue [30]. The capacity of highly macrophage-tropic envelopes to use low amounts of CD4 and/or CCR5 suggests that such var- iants could also confer a broader tropism among CD4 + T- cells (that express low amounts of these receptors) and contribute to CD4 + T-cell depletion late in disease if they are present in immune tissue. Several groups have also reported differences in the prop- erties of R5 virus isolates made from blood. Thus, virus isolates from late disease were reported to be more macro- phage-tropic than those from earlier stages [31-33]. In addition, Repits et al. described late disease isolates with increased replicative capacity and reduced sensitivity to entry inhibitors including TAK779 (CCR5 antagonist) and T20 (gp41 inhibitor) [34]. However, they did not test whether these late isolates could exploit low CD4 or infect macrophages. It is unclear whether the highly macro- phage-tropic envelopes that we have amplified from brain tissue and other sites, correspond to the late isolates described by other groups [31-34]. Recently, Dunfee et al. described a polymorphism in the C2 region of the CD4 binding site on gp120. Thus, 41% of their envelope sequences from brain tissue of patients with dementia carried an asparagine at residue 283 com- pared with 8% of envelopes from patients without dementia [35]. We also reported a predominance of N283 in highly macrophage-tropic brain envelopes compared to lymph node, blood and semen [27]. N283 was shown to increase the affinity of monomeric gp120 for CD4 [35]. More recently, the loss of a glycosylation site (N386) close to the CD4 binding loop on gp120 was reported to occur more frequently in HIV in the brain and was shown to contribute to increased R5 macrophage-tropism [36], an Retrovirology 2008, 5:5 http://www.retrovirology.com/content/5/1/5 Page 3 of 17 (page number not for citation purposes) observation that we have recently confirmed (Duenas- Decamp et al. Personal communication). How variation in R5 tropism impacts on the sensitivity of HIV-1 to neutralizing antibodies and entry inhibitors is unclear. We, and others have reported that R5 macro- phage-tropism correlated with increased resistance to anti-CD4 monoclonal antibodies (mabs), consistent with an increased affinity between gp120 and CD4. However, there was no correlation with sensitivity to the CCR5 antagonist, TAK779 [26,29]. Here, we have extensively analyzed the sensitivity of thirty-six envelopes from brain, LN, blood and semen to a range of reagents that block HIV-1 entry. All these envelopes were derived from patient material by PCR without culture and have there- fore not been altered by viral isolation procedures. Rea- gents tested for inhibition included soluble CD4 (sCD4) and tetrameric IgG-CD4 (PRO 542), BMS-378806; a small molecule that targets a site deep in the cleft that binds CD4, mabs to CD4 and CCR5, CCR5 antagonists, T20 and human mabs that recognize conserved neutralization epitopes on gp120 and gp41. Our results strongly suggest that R5 macrophage-tropism is primarily modulated by changes in the CD4 binding site on gp120 and in its affinity for CD4. Such changes impact on sensitivity to the CD4bs mab, b12 and may be driven by the presence or absence of neutralizing antibod- ies in vivo that target the CD4bs or proximal sites. If highly macrophage-tropic R5 variants are preferentially transmit- ted, then vaccines that generate antibodies to the CD4bs may be particularly effective at preventing viral transmis- sion. Results Macrophage-tropism of brain and lymph node envelopes Envelopes used here have been described previously [26,27] with the addition of SQ43 380.4. They are all R5, predominantly using CCR5 as a coreceptor [26,27]. Table 1 shows macrophage infectivity as a percentage of the titer recorded on HeLa TZM-BL cells as described previously [27]. Macrophage infectivity was highly variable. Enve- lopes that conferred macrophage infectivity of >0.5% of infectivity for HeLa TZM-BL cells were designated as mac- rophage-tropic and are shown by bold script in Table 1. This arbitrary designation allows for easy identification of these envelopes as grey symbols in subsequent figures. All but one brain envelope conferred macrophage infection. None of the env + pseudovirions carrying lymph node envelopes conferred significant macrophage infection. Table 1: Macrophage tropism of R5 envelopes studied. Patient Number Envelope Macrophage Infectivity (%) a Patient Number Envelope Macrophage Infectivity (%) a NA20 B59 16.9 b P1114 C95-65 0.029 B76 0.179 C96-26 0.097 B501 51.6 C98-15 32.4 LN3 <0.001 C98-18 2.21 LN8 <0.001 C98-27 0.144 LN10 0.030 C98-28 0.004 LN14 0.025 C98-67 0.003 LN16 0.036 P3 Q3 164 1.4 0.002 NA420 B13 0.335 Q3 180 6.4 0.003 B33 3.35 SQ3 196 10.1 0.012 B42 0.559 SQ3 197 9.3 0.338 LN40 0.009 SQ3 199 8.5 0.003 LN85 0.026 P31 Q31 350.1 0.05 NA118 B12 0.006 Q31 351.6 0.02 LN27 0.023 SQ31 308.2 0.02 LN33 0.023 P43 Q43 378.2 0.03 NA176 B93 8.2 SQ43 380.1 0.6 NA353 B27 12.6 SQ43 380.4 9.63 Controls AD8 4.60 SF162 6.25 YU2 6.36 JRFL 3.27 JRCSF 0.011 a Macrophage infectivity as a percent of infectivity recorded on HeLa TZM-BL cells. Most of this data is derived from that presented in Peters et al. [27] with the addition of SQ43 380.4. b Bolded percentages indicate envelopes that were designated as macrophage-tropic i.e. >0.5% of infectivity for HeLa TZM-BL cells. Retrovirology 2008, 5:5 http://www.retrovirology.com/content/5/1/5 Page 4 of 17 (page number not for citation purposes) Macrophage-tropic R5 envelopes were amplified less fre- quently from blood and semen of adults and in plasma of infants. The effect of variation in R5 envelope tropism on sensitivity to entry inhibitors and neutralizing antibodies In immune tissue where there are high levels of neutraliz- ing antibodies, the HIV-1 envelope may evolve to protect critical sites (e.g. the CD4bs) from antibodies. In contrast, the brain is enclosed by the blood brain barrier, which usually restricts immunoglobulin from entering [37,38]. HIV-1 variants replicating in the brain may therefore evolve stronger interactions with CD4 and/or CCR5 resulting from enhanced exposure of the CD4 and/or CCR5 binding sites, but become more vulnerable to anti- body neutralization. We tested the sensitivity of our panel of brain, LN, blood and semen envelopes to a range of entry inhibitors and monoclonal antibodies. The entry inhibitors specifically block interactions of envelope with CD4 or CCR5, or prevent gp41 conformational changes required for fusion, while monoclonal antibodies steri- cally inhibit infection by binding conserved envelope sites on virions. Inhibitors and antibodies that interfere with envelope:CD4 interactions Figure 1A shows that macrophage-tropic envelopes were more resistant to inhibition by the CD4 mab, Q4120, which binds domain 1 of CD4 and competes with enve- lope for binding to CD4. In contrast, the same macro- phage-tropic envelopes were more sensitive to soluble CD4 (sCD4) (Figure 1B) and to the more potent tetra- meric IgG-CD4 construct (PRO 542) (Figure 1C). We used two-tailed non-parametric Spearman analyses to evaluate whether macrophage-tropism correlated with sensitivity to these reagents. Importantly, such analyses do not rely on our arbitrary designation of macrophage-tropism but simply compare macrophage infectivity titers (Table 1) with IC50s for each inhibitor. Our results showed highly significant correlations between increasing macrophage- tropism and increased sensitivity to sCD4 and PRO 542 as well as with an increased resistance to Q4120 (Table 2). These results are consistent with an increased affinity of R5 macrophage-tropic gp120s for binding to CD4, although alternative explanations should also be consid- ered (see below). Statistical evaluations of correlations between R5 macrophage-tropism and sensitivity to differ- ent inhibitors are discussed more fully below and p values are shown in Table 2. We also tested the small molecule, BMS-378806, which was reported to inhibit gp120 binding to CD4 [39-41] and subsequent conformational changes [42]. BMS- 378806 is believed to bind into a deep hydrophobic chan- nel of unliganded gp120 close to and underneath the sites that bind to CD4. Thus, BMS-378806 may directly inhibit CD4 binding and also act to stabilize the unliganded form of the gp120 [43]. There was also a highly significant cor- relation between R5 macrophage-tropism and BMS- 378806 sensitivity (Table 2, see below). However, in con- trast to sCD4 and tetrameric IgG-CD4, BMS-378806 sen- sitivity decreased with increasing macrophage-tropism. We next tested envelope sensitivity to the CD4bs mab, b12 (Figure 2). All but one macrophage-tropic env con- ferred sensitivity to b12 neutralization, while many non- macrophage-tropic envelopes were resistant at 50 μg/ml antibody. These results indicate that there is also a strong relationship between b12 sensitivity and R5 envelope tro- pism, although this did not result in a statistically signifi- cant overall correlation (Table 2). Sensitivity of R5 envelopes to reagents that target envelope:CCR5 interactions The mouse mab 17b binds to a conserved CD4-induced epitope on gp120 that overlaps the conserved part of the coreceptor binding site (not shown). None of the patient envelopes were inhibited by 17b, suggesting that this site is not more exposed on macrophage-tropic envelopes. However, 17b did neutralize T-cell line adapted HIV-1 iso- lates NL4.3 and HXBc2 (not shown). In contrast, both CCR5 antagonists TAK779 and SCH350581 inhibited all the envelopes regardless of their tropism for macrophages (Figures 3A and 3B). As expected SCH350581 was a substantially more potent inhibitor compared to TAK779. In contrast to the strong correlations observed between macrophage-tropism and reagents that inhibited gp120:CD4 interactions, overall correlations with sensitivity to CCR5 antagonists were not significant (Table 2). CCR5 antagonists bind to a cavity in between the transmembrane domains of CCR5. It is believed that these reagents confer a CCR5 structure that is no longer recognized by the HIV envelope [44,45]. Thus, although CCR5 antagonists compete with HIV for binding CCR5, they are not competing for the same site. It was possible that CCR5-specific inhibitors that compete directly with HIV for binding the extracellular regions of CCR5 may confer a different pattern of envelope sensitiv- ity. We therefore tested the anti-CCR5 monoclonal anti- body, 2D7, which binds ECL2 of CCR5, a region that interacts with sites on the V3 loop of envelope. Due to limiting amounts of 2D7, we tested only brain and LN envelopes from patients NA420 and NA20, with JRFL and JRCSF as controls. Figure 3C shows a trend of brain mac- rophage-tropic envelopes being more sensitive to 2D7 compared to LN envelopes, although this did not reach statistical significance (p = 0.0839). NA20 LN14 was a clear 'outlier' from other LN envelopes and was among the Retrovirology 2008, 5:5 http://www.retrovirology.com/content/5/1/5 Page 5 of 17 (page number not for citation purposes) Sensitivity of HIV-1 R5 envelopes to reagents that interfere with gp120:CD4 interactionsFigure 1 Sensitivity of HIV-1 R5 envelopes to reagents that interfere with gp120:CD4 interactions. Pseudovirions carrying envelopes encoded by envelope genes amplified from patient samples were tested for sensitivity to inhibition by (A) anti-CD4 mab, Q4120, (B) sCD4, (C) PRO 542 and (D) BMS-378806. Macrophage-tropic envelopes (light symbols) were more sensitive to sCD4 and PRO 542 compared to non-macrophage-tropic envelopes (dark symbols) but were more resistant to the anti-CD4 mab, Q4120. $' 1$% 1$% 1$% 1$% 1$% 1$% 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 -5&6) 6) -5)/ 1$% 1$% 1$% 1$/1 1$/1 1$/1 <8 & & & & & & & 4 4 4 4 4 64 64 64 64 64 64 ! 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 & & & & & & & 4 4 4 4 4 64 64 64 64 <8 -5)/ -5&6) $' 6) 1$% 1$% 1$% 1$% 1$% 1$% 1$/1 1$/1 1$/1 1$/1 & & & & & & & 4 4 4 4 64 64 64 64 -5&6) $' <8 6) -5)/ ! 1$/1 1$/1 1$/1 1$/1 1$/1 64 64 4 1$% 1$% 1$% 64 64 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 & & & & & & 4 4 4 4 4 64 64 64 64 <8 -5)/ -5&6) $' 6) 64 64 1$/1 & ! %UDLQ /1 3HGLDWULF SODVPD $GXOW EORRG $GXOW VHPHQ &RQWUROV PJPO PJPOPJPO Q0 ,&V $4 %V&' &352 '%06 Retrovirology 2008, 5:5 http://www.retrovirology.com/content/5/1/5 Page 6 of 17 (page number not for citation purposes) envelopes most sensitive to all three CCR5 inhibitors (see discussion below). Inhibition by human mab, 2G12 that targets gp120 glycosylation groups The human monoclonal antibody, 2G12, neutralizes HIV- 1 isolates mainly from clade B via relatively conserved gly- cosylation structures on gp120 [46,47]. Clear variation in sensitivity to 2G12 was noted, with most envelopes sensi- tive, while some were resistant (Figure 4). Of note, several brain-derived envelopes were resistant including NA420 envelopes B13, B33 and B42 as well as NA353 B27 and YU2. A significant correlation between macrophage-tro- pism and decreased 2G12 sensitivity was noted. Table 3 lists the presence or absence of glycosylation sites previ- ously reported to be important for 2G12 binding [46,47]. All five of the NA420 envelopes lacked the critical poten- tial glycosylation site at N339, while B13 and B33 also lacked N386. The loss of these glycosylation sites likely contributes to 2G12 resistance for some of these enve- lopes. However, LN40 is sensitive to 2G12 despite lacking N339, and NA353 B27 is resistant even though all the Table 2: Non-parametric two-tailed Spearman analysis for correlations between R5 envelope macrophage-tropism and sensitivity to entry inhibitors. Inhibitor/Antibody Target of reagent Stage of entry blocked 3 . Correlation with Macrophage-tropism (p Values) Q4120 CD4 env: CD4 interactions <0.0001** sCD4 gp120, CD4bs env: CD4 interactions <0.0001** PRO 542 (IgG-CD4) gp120, CD4bs env: CD4 interactions <0.0001** BMS-378806 gp120, CD4bs channel 1 . env: CD4 interactions 0.0002** b12 gp120, overlapping CD4bs 2 . 0.6843 TAK779 CCR5 env: CCR5 interactions 0.7964 SCH350581 CCR5 env: CCR5 interactions 0.7587 2D7 CCR5 env: CCR5 interactions 2G12 gp120 glycan env: CCR5 interactions 0.0138* T20 gp41 conformational changes gp41 conformational changes 0.7061 2F5 gp41 membrane proximal region gp41 conformational changes 4 . 0.3741 4E10 gp41 membrane proximal region gp41 conformational changes 4 . 0.3502 1. BMS-378806 binds to a hydrophobic channel deep in the channel targeted by CD4 [42]. 2. Mab b12 binds an epitope that overlaps the CD4bs [57]. 3. Mab 2G12 binds to a glycan on gp120. 2G12 blocks env:CCR5 interactions but may also block earlier stages of entry [73]. 4. Mabs 2F5 and 4E10 block gp41 conformational changes but may also block earlier stages of entry [73]. * Significant (p ≤ 0.05). ** Highly significant (p ≤ 0.01) Sensitivity of HIV-1 R5 envelopes to the CD4bs mab, b12Figure 2 Sensitivity of HIV-1 R5 envelopes to the CD4bs mab, b12. Pseudovirions carrying envelopes encoded by envelope genes ampli- fied from patient samples were tested for sensitivity to inhibition by b12. All but one of the macrophage-tropic envelopes (light symbols) were sensitive to b12, while many non-macrophage-tropic envelopes (dark symbols) were resistant. %UDLQ /1 3HGLDWULF SODVPD $GXOW EORRG $GXOW VHPHQ &RQWUROV ! 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 & & & & & & & 4 4 4 4 4 64 64 64 -5&6) $' <8 6) -5)/ 64 64 64 ,&PJPO Retrovirology 2008, 5:5 http://www.retrovirology.com/content/5/1/5 Page 7 of 17 (page number not for citation purposes) 2G12-implicated glycosylation sites are present. The determinants for 2G12 resistance and sensitivity for these envelopes are therefore unclear and will require further investigation to define precisely. Inhibition by mabs 4E10 and 2F5 that bind membrane proximal epitopes on gp41 Figures 5A, 5B and Table 2 show that there was also no clear correlation between macrophage-tropism and sensi- tivity to the mabs 4E10 and 2F5 that bind conserved membrane proximal epitopes on gp41. Of the envelopes that conferred 2F5 resistance, only NA420 B42 (ELD- NWA) did not contain the core ELDKWA epitope associ- ated with 2F5 sensitivity [48-50]. Inhibition by T20 that inhibits formation of the gp41 6- helix bundle required for fusion All envelopes tested were sensitive to T20 (Figure 5C). However, no overall correlation was observed between T20 sensitivity and R5 macrophage-tropism. The envelope determinants of resistance and sensitivity to T20 shown here are unclear. All envelopes carried the GIV 36–38 motif in HR1, the site where resistance mutations fre- quently appear [51,52]. Sensitivity of HIV-1 R5 envelopes to reagents that interfere with gp120:CCR5 interactionsFigure 3 Sensitivity of HIV-1 R5 envelopes to reagents that interfere with gp120:CCR5 interactions. Pseudovirions carrying envelopes encoded by envelope genes amplified from patient samples were tested for sensitivity to inhibition by (A) TAK779, (B) SCH350581 and (C) anti-CCR5, 2D7. Macrophage-tropic envelopes (light symbols) and non-macrophage-tropic envelopes (dark symbols) were examined. Statistical analysis showed no overall correlation between macrophage-tropism and sensitivity to TAK779 or SCH350581 (Table 2). 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 & & & & & & & 4 4 4 4 4 64 64 64 64 <8 6) -5)/ 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 & & & & & & & 4 4 4 4 4 64 64 64 64 -5&6) $' <8 6) -5)/ %UDLQ /1 3HGLDWULF SODVPD $GXOW EORRG $GXOW VHPHQ &RQWUROV ,&Q0 64 64 1$% 1$% 1$% 1$% 1$% 1$% 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 -5)/ -5&6) %UDLQ /1 &RQWUROV 64 64 -5&6) $' ,&PJPO ,&P0 $7$. %6&+ &' Retrovirology 2008, 5:5 http://www.retrovirology.com/content/5/1/5 Page 8 of 17 (page number not for citation purposes) Summary of correlations between macrophage-tropism and sensitivity to inhibitors Table 2 and Figure 6 show that R5 macrophage-tropism correlates with sensitivity to inhibitors that interfere with gp120:CD4 interactions. There was also a significant cor- relation between increased macrophage-tropism and with decreased sensitivity to 2G12 neutralization. No overall correlation was noted between macrophage-tropism and sensitivity to the gp41 mabs or T20. In summary, R5 mac- rophage-tropism correlated with sensitivity to reagents that interfere with gp120:CD4 binding but not with inhibitors that prevent gp120, CCR5 interactions or gp41 conformational changes. Intrapatient variation in sensitivity to b12, and CCR5 antagonists Although all but one of the macrophage-tropic brain envelopes were sensitive to b12 and most non-macro- phage-tropic envelopes were resistant, there was not a sig- nificant correlation between macrophage-tropism and b12 sensitivity. However, Figure 7 shows dose dependent b12 neutralization profiles for brain and lymph node envelopes from patients NA20 and NA420. For both patients, all macrophage-tropic brain envelopes were more sensitive to b12, while non-macrophage-tropic LN envelopes were resistant. Figure 7 also shows dose dependent variation in TAK779 and SCH350581 for envelopes from patients NA20 and NA420. For both patients, the macrophage-tropic brain envelopes were more sensitive to TAK779 and SCH350581 compared to most or all of the non-macro- phage-tropic LN envelopes. These results do not support an increase in envelope: CCR5 affinity for highly macro- phage-tropic brain envelopes as suggested by an earlier study [28]. Together these results show clear intrapatient and tissue modulation of envelope sensitivity to b12 and to TAK779 and SCH350581. Similar tissue specific sensitivity was also observed for the NA20 and NA420 envelopes with PRO 542 and Q4120 (Figure 7), sCD4 (not shown), and 2D7 (Figure 3C). Discussion For the majority of HIV + patients, AIDS and death result from replication by HIV-1 R5 viruses in the absence of detectable CXCR4-using variants. The mechanisms of CD4 + T-cell loss and immune destruction conferred by R5 viruses are unclear. Whether R5 variants with increased virulence emerge in late disease and contribute to CD4 + T- cell loss remains an open question. Several groups have reported the presence of R5 variants in late disease that are highly macrophage-tropic [31-33]. The capacity of highly macrophage-tropic R5 viruses to infect cells with low lev- els of CD4 and/or CCR5 may confer a broader tropism for CD4 + T-cells and exacerbate their depletion late in disease. Our previous studies have highlighted the variation of R5 viruses at different tissue sites [26,27], showing that highly macrophage-tropic R5 envelopes predominated in brain tissue but were less prevalent in immune tissue (lymph node), blood and semen. In this study we have examined the sensitivity of enve- lopes amplified from these different sites to a range of inhibitors and antibodies that target CD4, CCR5, or vari- Sensitivity of HIV-1 R5 envelopes to 2G12Figure 4 Sensitivity of HIV-1 R5 envelopes to 2G12. Pseudovirions carrying envelopes encoded by envelope genes amplified from patient samples were tested for sensitivity to inhibition by 2G12. Macrophage-tropic envelopes (light symbols) and non-macro- phage-tropic envelopes (dark symbols) were examined. Statistical analysis showed a significant correlation between macro- phage-tropism and sensitivity to 2G12. 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% ! 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 ,&PJPO & & & & & & & 4 4 4 4 4 64 64 64 <8 6) -5)/ 64 64 64 $' -5&6) %UDLQ /1 3HGLDWULF SODVPD $GXOW EORRG $GXOW VHPHQ &RQWUROV Retrovirology 2008, 5:5 http://www.retrovirology.com/content/5/1/5 Page 9 of 17 (page number not for citation purposes) ous sites on the HIV envelope and block different stages in the entry process. We focused entirely on R5 envelopes and did not include R5X4 or X4 envs. We evaluated whether the variation in macrophage-tropism estimated for all R5 envelopes correlated with sensitivity to each of these reagents using a two-tailed, non-parametric Spear- man test with 95% confidence limits. Care must be taken in interpreting these analyses since the panel of envelopes evaluated included several sets that originated from indi- vidual subjects i.e. thirty-six envelopes from nine subjects. Table 3: R5 envelopes sensitivity to 2G12 neutralization and conservation of critical potential N-linked glycosylation sites. Envelope 2G12 sensitivity N295 N332 N339 N386 N392 N448 NA20 B59 +/- ++++++ B76 + ++++++ B501 +/- ++++++ LN3 + ++++++ LN8 + ++++++ LN10 + ++++++ LN14 + ++++++ LN16 + ++++++ NA420 B13 - + + - - + + B33 - + + - - + + B42 +/- ++- +++ LN40 + ++ - +++ LN85 - ++ - +++ NA118B12 + ++++++ LN27 + ++++++ LN33 + + + + - + + NA176B93 + ++++++ NA353B27 - ++++++ P-1114 C95-65 +/- + + - + + + C96-26 +/- ++++++ C98-15 + ++++++ C98-18 + ++++++ C98-27 + ++++++ C98-28 + ++++++ C98-67 + ++++++ P3 Q3 164 1.4 + ++++++ Q3 180 6.4 +/- ++++++ SQ3 196 10.1 + ++++++ SQ3 197 9.3 + ++++++ SQ3 199 8.5 + ++++++ P31 Q31 350.1 +/- ++++++ Q31 351.6 +/- ++++++ SQ31 308.2 +/- ++++++ P43 Q43 378.2 - +++++ - SQ43 380.1 - +++++ - SQ43 380.4 - +++++ - ControlsAD8 +/- ++++++ SF162 + ++++++ YU2 - ++- +++ JRFL + ++++++ JRCSF + ++++++ For 2G12 sensitivity; -, IC50 > 50 μg/ml; +/-, IC50 20–50 μg/ml; +, IC50 < 20 μg/ml. Retrovirology 2008, 5:5 http://www.retrovirology.com/content/5/1/5 Page 10 of 17 (page number not for citation purposes) Thus, it is possible that envelopes with a particular pheno- type may be predominant in an individual due to a founder effect or other extenuating circumstances and shift the statistical significance in its favor. Nonetheless, envelope sensitivity to reagents that block CD4: gp120 interactions (sCD4, IgG-CD4 and Q4120) correlated with R5 macrophage-tropism with very high significance. Thus, our data strongly indicates that R5 macrophage tropism predominantly correlates with sensitivity to reagents that interfere with envelope binding to CD4. Macrophage- tropic R5 viruses were more sensitive to sCD4 and tetrav- alent IgG-CD4 (PRO 542), but more resistant to inhibi- tion by the CD4 mab, Q4120. These data are consistent with an increased envelope affinity for CD4, although there are other potential mechanisms e.g. gp120 shed- ding, that could explain different sensitivities to sCD4 and PRO 542. An increased envelope affinity for CD4 could result from gp120 substitutions that that result in tighter binding to CD4, in better exposure of the CD4 binding site, or both. Certainly brain-derived envelopes are more likely to carry the N283 in the C2 CD4 binding site as reported by Dunfee et al. [35] and confirmed by our group Sensitivity of HIV-1 R5 envelopes to reagents that target gp41 and inhibit conformational changes in gp41 required for fusionFigure 5 Sensitivity of HIV-1 R5 envelopes to reagents that target gp41 and inhibit conformational changes in gp41 required for fusion. Pseudovirions carrying envelopes encoded by envelope genes amplified from patient samples were tested for sensitivity to inhi- bition by (A) mab 2F5, (B) mab 4E10 and (C) T20. Macrophage-tropic envelopes (light symbols) and non-macrophage-tropic envelopes (dark symbols) were examined. Statistical analysis showed no overall correlation between macrophage-tropism and sensitivity to 2F5, 4E10 or T20. However, when just brain and lymph node envelopes were evaluated, a correlation between macrophage-tropism and increased sensitivity to T20 was nearly reached (p = 0.0658). %UDLQ /1 3HGLDWULF SODVPD $GXOW EORRG $GXOW VHPHQ &RQWUROV 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 & & & & & & & 4 4 4 4 4 64 64 64 64 <8 6) -5)/ 1$% 64 64 $' -5&6) 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 ,&PJPO & & & & & & & 4 4 4 4 4 64 64 64 64 <8 6) -5)/ 64 $' -5&6) 1$% 1$/1 1$/1 64 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$% 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 1$/1 & & & & & & & 4 4 4 4 4 64 64 64 64 <8 6) -5)/ 64 $' -5&6) 1$% 1$/1 1$/1 64 ! ! $) %( &7 [...]... determinants of 2G12 sensitivity and resistance are unclear but must include other determinants in addition to these glycosylation sites interactions with CD4 and limited to infection of cells that carry high amounts of CD4 e.g CD4+ T-cells Curiously increased R5 macrophage-tropism may have resulted in increased resistance to 2G12 but increased sensitivity to b12 Thus a vaccine designed to induce both b12-like... implicated in BMS-378806 binding which did not associate with sensitivity (not shown) [43] The variation in BMS-378806 sensitivity must therefore be due to other mechanisms but could be explained by changes in envelope: CD4 affinities Protection of the CD4 binding site may be conferred by V1V2 shielding or by glycan groups [53-57] Recently, Dunfee et al reported that a glycosylation site at N386 may protect... envelope sensitivity to BMS-378806, a reagent reported to inhibit gp120 :CD4 interactions [39,40] and gp120 conformational changes [42] Since BMS-378806 is a small molecule, binding to gp120 will not be restricted by variable loops or glycan residues Intriguingly, decreasing sensitivity to BMS-378806 correlated with increasing R5 macrophage-tropism There was only minimal variation in the amino acids... correlated with an increased sensitivity to PRO 542 but decreased sensitivity to Q4120 and BMS378806 HIV-1 R5 macrophage-tropism also correlated with sensitivity to 2G12 but not with b12, TAK779, SCH350581 or T20 (see complete list of p values in Table 2) [27] N283 appears to confer a higher affinity for CD4 by facilitating the formation of a hydrogen bond between N283 on envelope gp120 and Q40 on CD4 [35]... reagents that inhibit gp120 interactions with Intrapatient variation of HIV-1 R5 envelope macrophage-tropism and sensitivity to reagents that inhibit gp120 interactions with CD4 and CCR5 Brain-derived envelopes (light symbols) from patient NA420 (left panels) and NA20 (right panels) were more sensitive to PRO 542, b12, TAK779 and SCH350581, but more resistant to anti -CD4, Q4120, compared to LN-derived... strongly indicate that macrophagetropism is modulated by changes in gp120 that predominantly impact on the CD4 binding site consistent with an increased gp120 :CD4 affinity Our results have relevance for therapies that target HIV entry and for the design of vaccines that aim to induce neutralizing antibodies Methods Patients and HIV-1 envelopes The subjects and envelopes described in this study have... inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitorbound receptor for entry J Virol 2006, 81:2359-2371 Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, Kuhmann SE: HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry Virology 2006, 361:212-228 Scanlan CN, Pantophlet... variation in HIV-1 R5 macrophage-tropism relates to sensitivity to neutralizing antibodies that target conserved envelope epitopes and to reagents that inhibit virus entry We have investigated HIV-1 envelopes amplified directly from patient material without culture Such envelopes are expected to represent those in vivo and have a distinct advantage over primary Page 13 of 17 (page number not for citation... Retrovirology 2008, 5:5 http://www.retrovirology.com/content/5/1/5 isolates that will have been altered by culture Our data demonstrate considerable phenotypic variation conferred by R5 envelopes that impacts on macrophage-tropism and sensitivity to entry inhibitors including the CD4 binding site mab, b12 It is currently unclear whether this variation affects the capacity of R5 viruses to transmit... substantially more sensitive to b12 compared to LN-derived envelopes Together, these results are consistent with selection by neutralizing antibodies that target the CD4bs or proximal epitopes in immune lymphoid tissue but not in brain So, it seems probable that neutralizing antibodies present in immune tissue play an important role in selecting for envelopes that protect the CD4bs via variable loops, glycosylation . correlated with sensitivity to inhibition by reagents that inhibited gp120 :CD4 interactions. Thus, increasing macrophage-tropism was associated with increased sensitivity to soluble CD4 and to IgG -CD4. correlated with sensitivity to reagents that interfere with gp120 :CD4 binding but not with inhibitors that prevent gp120, CCR5 interactions or gp41 conformational changes. Intrapatient variation in sensitivity. envelopes to reagents that interfere with gp120 :CD4 interactionsFigure 1 Sensitivity of HIV-1 R5 envelopes to reagents that interfere with gp120 :CD4 interactions. Pseudovirions carrying envelopes